Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.

Synthetic C peptides, corresponding to the C helix of the HIV type 1 (HIV-1) gp41 envelope protein, are potent inhibitors of HIV-1 membrane fusion. One such peptide is in clinical trials. The crystal structure of the gp41 core, in its proposed fusion-active conformation, is a trimer of helical hairpins in which three C helices pack against a central coiled coil. Each C helix shows especially prominent contacts with one of three symmetry-related, hydrophobic cavities on the surface of the coiled coil. We show that the inhibitory activity of the C peptide C34 depends on its ability to bind to this coiled-coil cavity. Moreover, examining a series of C34 peptide variants with modified cavity-binding residues, we find a linear relationship between the logarithm of the inhibitory potency and the stability of the corresponding helical-hairpin complexes. Our results provide strong evidence that this coiled-coil cavity is a good drug target and clarify the mechanism of C peptide inhibition. They also suggest simple, quantitative assays for the identification and evaluation of analogous inhibitors of HIV-1 entry.

[1]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[2]  Reinhard Jahn,et al.  Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution , 1998, Nature.

[3]  A. Gronenborn,et al.  Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.

[4]  R. Lamb,et al.  A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. , 1998, Virology.

[5]  P S Kim,et al.  Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[7]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[8]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[9]  Benedikt Westermann,et al.  SNAREpins: Minimal Machinery for Membrane Fusion , 1998, Cell.

[10]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[11]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[12]  R. Blumenthal,et al.  Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors* , 1998, The Journal of Biological Chemistry.

[13]  Christos,et al.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Schreiber,et al.  Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale. , 1997, Chemistry & biology.

[15]  P. S. Kim,et al.  A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. , 1997, Journal of biomolecular structure & dynamics.

[16]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Scheller,et al.  Structural Organization of the Synaptic Exocytosis Core Complex , 1997, Neuron.

[18]  Reinhard Jahn,et al.  Structure and Conformational Changes in NSF and Its Membrane Receptor Complexes Visualized by Quick-Freeze/Deep-Etch Electron Microscopy , 1997, Cell.

[19]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[20]  J. Ellman,et al.  Combinatorial chemistry and new drugs. , 1997, Scientific American.

[21]  R. Compans,et al.  Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. , 1996, Virology.

[22]  Lorenz M. Mayr,et al.  Identification of d-Peptide Ligands Through Mirror-Image Phage Display , 1996, Science.

[23]  D. Lambert,et al.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. S. Kim,et al.  Retrovirus envelope domain at 1.7 angstrom resolution. , 1996, Nature structural biology.

[25]  Y. Shai,et al.  A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus‐cell fusion: an emerging similarity with functional domains of other viruses. , 1995, The EMBO journal.

[26]  D. Bolognesi,et al.  A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion , 1995, Journal of virology.

[27]  J. C. Chabala.  Solid-phase combinatorial chemistry and novel tagging methods for identifying leads. , 1995, Current opinion in biotechnology.

[28]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[29]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[31]  R. Andino,et al.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses , 1994, Journal of virology.

[32]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[33]  P. S. Kim,et al.  Peptide ‘Velcro’: Design of a heterodimeric coiled coil , 1993, Current Biology.

[34]  G. Salitra,et al.  Nested fullerene-like structures , 1993, Nature.

[35]  R. L. Baldwin,et al.  Aromatic side-chain contribution to far-ultraviolet circular dichroism of helical peptides and its effect on measurement of helix propensities. , 1993, Biochemistry.

[36]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[37]  J. Sodroski,et al.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein , 1993, Journal of virology.

[38]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[39]  J. Sodroski,et al.  Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. , 1989, Journal of acquired immune deficiency syndromes.

[40]  W. J. Becktel,et al.  Protein stability curves , 1987, Biopolymers.

[41]  C. Li,et al.  Adrenocorticotropin. 47. Synthesis and biological activity of adrenocorticotropic peptides modified at the tryptophan position. , 1975, Journal of medicinal chemistry.

[42]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.